Milvexian for Ischemic Stroke

Phase-Based Progress Estimates
Insight Hospital and Medical Center Chicago, Chicago, ILIschemic StrokeMilvexian - Drug
All Sexes
What conditions do you have?

Study Summary

This trial tests if a drug can reduce the risk of stroke recurrence.

Eligible Conditions
  • Ischemic Stroke

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

0 Primary · 3 Secondary · Reporting Duration: Up to global targeted endpoint date (approximately 41 months)

Up to Day 90
Time to First Occurrence of Ischemic Stroke
Month 41
Time to First Occurrence of any Component of Major Adverse Vascular Events (MAVE)
Time to First Occurrence of any Component of the Composite of Cardiovascular Death (CVD), Myocardial Infraction (MI), or Ischemic Stroke

Trial Safety

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

15000 Total Participants · 2 Treatment Groups

Primary Treatment: Milvexian · Has Placebo Group · Phase 3

Experimental Group · 1 Intervention: Milvexian · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to global targeted endpoint date (approximately 41 months)

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
934 Previous Clinical Trials
6,354,231 Total Patients Enrolled
Bristol Myers Squibb Company (BMS)UNKNOWN
1 Previous Clinical Trials
20 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
717 Previous Clinical Trials
3,936,372 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are taking or planning to take certain medications that affect blood clotting, as recommended by international and/or local guidelines. If you take acetyl salicylic acid (ASA), you can only take a low dose (75 to 100 milligrams per day). It is okay to take a higher initial dose of these medications if it is part of your standard-of-care treatment.

Who else is applying?

What state do they live in?
New York100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

Frequently Asked Questions

How much risk is associated with Milvexian usage?

"Our risk assessment yielded Milvexian a score of 3 on the 1-3 scale due to pre-existing data that point towards its efficacy and extensive evidence vouching for its safety." - Anonymous Online Contributor

Unverified Answer

Are there a range of healthcare facilities performing this clinical test within the state?

"Glendale Adventist Medical Center in Glendale, California, Southland Neurology in Los Alamitos, Colorado and Kaiser Permanente Northern California in Oakland, Delaware are 3 of the 81 enrolment centres for this study." - Anonymous Online Contributor

Unverified Answer

Are there any open positions for individuals to join this trial?

"According to, the trial is at present not welcoming new enrolments. This investigation was initially made visible on February 9th 2023 and most recently modified on January 19th 2023. While this particular study has reached its capacity for volunteers, there are still 1303 other trials that need participants now." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.